Corcept Therapeutics (0I3Q) Ratios
Corcept Therapeutics Ratios
GB:0I3Q's free cash flow for Q2 2026 was $31.02M. For the 2026 fiscal year, GB:0I3Q's free cash flow was decreased by $-2.53M and operating cash flow was $33.54M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.92 | 3.35 | 4.39 | 6.89 | 5.60 |
| Quick Ratio | 2.85 | 3.26 | 4.31 | 6.80 | 5.50 |
| Cash Ratio | 0.73 | 0.91 | 1.30 | 0.91 | 1.63 |
| Solvency Ratio | 0.54 | 0.88 | 0.93 | 1.26 | 2.41 |
| Operating Cash Flow Ratio | 0.85 | 1.41 | 1.22 | 1.66 | 3.53 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 238.92 | 841.32 | 105.27 | 319.19 |
| Net Current Asset Value | $ 296.62M | $ 310.64M | $ 343.82M | $ 417.67M | $ 218.51M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.29 | 1.24 | 1.23 | 1.16 | 1.13 |
| Debt Service Coverage Ratio | 0.00 | 171.95 | 595.41 | 86.72 | 219.50 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.06 | 0.07 | 0.00 | 0.01 | 0.00 |
| Net Debt to EBITDA | -1.67 | -0.74 | -1.25 | -0.57 | -0.60 |
| Profitability Margins | |||||
| Gross Profit Margin | 98.30% | 98.39% | 98.66% | 98.66% | 98.56% |
| EBIT Margin | 8.73% | 23.92% | 22.24% | 28.03% | 34.16% |
| EBITDA Margin | 8.98% | 24.12% | 22.46% | 28.34% | 34.96% |
| Operating Profit Margin | 5.88% | 20.29% | 22.24% | 28.03% | 34.01% |
| Pretax Profit Margin | 8.73% | 23.92% | 25.82% | 28.91% | 34.16% |
| Net Profit Margin | 13.09% | 20.70% | 22.00% | 25.24% | 30.74% |
| Continuous Operations Profit Margin | 13.09% | 20.92% | 22.00% | 25.24% | 30.74% |
| Net Income Per EBT | 149.94% | 86.53% | 85.21% | 87.29% | 90.01% |
| EBT Per EBIT | 148.36% | 117.92% | 116.10% | 103.16% | 100.42% |
| Return on Assets (ROA) | 11.91% | 16.62% | 17.08% | 17.38% | 26.55% |
| Return on Equity (ROE) | 15.38% | 20.56% | 20.95% | 20.21% | 29.94% |
| Return on Capital Employed (ROCE) | 6.68% | 19.57% | 20.75% | 22.04% | 33.09% |
| Return on Invested Capital (ROIC) | 6.67% | 17.09% | 17.68% | 19.20% | 29.74% |
| Return on Tangible Assets | 11.91% | 16.62% | 17.08% | 17.38% | 26.55% |
| Earnings Yield | 2.76% | 2.69% | 3.16% | 4.68% | 4.91% |
| Efficiency Ratios | |||||
| Receivables Turnover | 12.74 | 11.62 | 8.49 | 8.58 | 12.61 |
| Payables Turnover | 0.32 | 0.71 | 0.37 | 0.45 | 0.76 |
| Inventory Turnover | 1.01 | 0.88 | 0.84 | 0.88 | 1.06 |
| Fixed Asset Turnover | 117.63 | 84.24 | 1531.35 | 226.27 | 241.41 |
| Asset Turnover | 0.91 | 0.80 | 0.78 | 0.69 | 0.86 |
| Working Capital Turnover Ratio | 2.34 | 1.97 | 1.24 | 1.24 | 1.13 |
| Cash Conversion Cycle | -746.96 | -68.02 | -501.38 | -355.72 | -103.75 |
| Days of Sales Outstanding | 28.66 | 31.40 | 43.00 | 42.56 | 28.95 |
| Days of Inventory Outstanding | 361.93 | 416.32 | 435.34 | 413.46 | 344.75 |
| Days of Payables Outstanding | 1137.56 | 515.74 | 979.72 | 811.74 | 477.45 |
| Operating Cycle | 390.59 | 447.72 | 478.34 | 456.02 | 373.70 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.37 | 1.92 | 1.23 | 1.13 | 1.45 |
| Free Cash Flow Per Share | 1.37 | 1.90 | 1.23 | 1.12 | 1.45 |
| Dividend Paid and CapEx Coverage Ratio | 672.97 | 91.19 | 913.95 | 291.34 | 357.98 |
| Capital Expenditure Coverage Ratio | 672.97 | 91.19 | 913.95 | 291.34 | 357.98 |
| Operating Cash Flow Coverage Ratio | 23.25 | 28.56 | 841.32 | 105.27 | 319.19 |
| Operating Cash Flow to Sales Ratio | 0.19 | 0.29 | 0.26 | 0.30 | 0.46 |
| Free Cash Flow Yield | 3.92% | 3.77% | 3.77% | 5.53% | 7.31% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 36.63 | 37.23 | 31.69 | 21.39 | 20.35 |
| Price-to-Sales (P/S) Ratio | 4.75 | 7.71 | 6.97 | 5.40 | 6.26 |
| Price-to-Book (P/B) Ratio | 5.58 | 7.65 | 6.64 | 4.32 | 6.09 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 25.49 | 26.55 | 26.51 | 18.09 | 13.68 |
| Price-to-Operating Cash Flow Ratio | 25.45 | 26.26 | 26.48 | 18.03 | 13.64 |
| Price-to-Earnings Growth (PEG) Ratio | -1.24 | 1.15 | 4.30 | -10.37 | 3.74 |
| Enterprise Value Multiple | 51.20 | 31.21 | 29.80 | 18.47 | 17.29 |
| Enterprise Value | 3.50B | 5.08B | 3.23B | 2.10B | 2.21B |
| EV to EBITDA | 51.20 | 31.21 | 29.80 | 18.47 | 17.29 |
| EV to Sales | 4.60 | 7.53 | 6.69 | 5.23 | 6.05 |
| EV to Free Cash Flow | 24.69 | 25.94 | 25.44 | 17.54 | 13.22 |
| EV to Operating Cash Flow | 24.65 | 25.65 | 25.41 | 17.48 | 13.18 |
| Tangible Book Value Per Share | 6.24 | 6.58 | 4.89 | 4.70 | 3.25 |
| Shareholders’ Equity Per Share | 6.24 | 6.58 | 4.89 | 4.70 | 3.25 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.50 | 0.13 | 0.15 | 0.13 | 0.10 |
| Revenue Per Share | 7.33 | 6.54 | 4.66 | 3.76 | 3.16 |
| Net Income Per Share | 0.96 | 1.35 | 1.02 | 0.95 | 0.97 |
| Tax Burden | 1.50 | 0.87 | 0.85 | 0.87 | 0.90 |
| Interest Burden | 1.00 | 1.00 | 1.16 | 1.03 | 1.00 |
| Research & Development to Revenue | 0.33 | 0.37 | 0.38 | 0.33 | 0.31 |
| SG&A to Revenue | 0.59 | 0.42 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.11 | 0.09 | 0.10 | 0.11 | 0.12 |
| Income Quality | 1.45 | 1.40 | 1.20 | 1.19 | 1.49 |
Currency in USD